Zambon and Seqirus have announced that they have entered into a long-term partnership covering Zambon’s Parkinson’s Disease product, in Australia and New Zealand.
Zambon will be responsible for product supply and Seqirus will undertake registration and commercialisation of the product.
Parkinson’s Disease is one of the most common neurological illnesses in Australia, with approximately 70,000 Australians living with Parkinson’s.
It is a chronic, progressive, incurable, complex and disabling neurological condition that affects people from all walks of life. Parkinson’s is categorised by clinicians as a “movement disorder.” But, in many cases, it results in impaired speech and various mental health issues, such as depression and problems with memory and sleep.
The collaboration with Zambon consolidates Seqirus’ position of being a leading inlicensing partner in the Australian and New Zealand market.
“We recognise that access to more therapy options is very important to Australian healthcare professionals and Parkinson’s sufferers,” said Seqirus’ VP Commercial Operations, Dr Lorna Meldrum. “We are delighted to work with Zambon for the distribution, marketing and sales of Zambon’s Parkinson’s product, which is an important addition to Seqirus’ growing product range and further strengthens our broad portfolio of inlicensed medicines in Australia,” she said.
Roberto Tascione, CEO of Zambon, said: “Expanding the reach of Zambon’s products by entering new growth markets is an important part of our strategy. Seqirus is an attractive partner being a large local pharmaceutical company in Australia with a prominent track record in neurology. Australia and New Zealand are markets with resilient economies, substantial disease prevalence and established Parkinson’s Disease markets.”